生命科学资讯
生物技术与制药领域的最新动态
ARPA-H director eyes future beyond vaccines, ‘winning the biotech race’ against China
Abbott, AtaCor join forces on extravascular defibrillator implant
J&J, Isomorphic sign research deal for AI-made molecules
安捷伦科技(A)获汇丰银行首次覆盖给予“买入”评级 | 股票新闻 - GuruFocus
Agilent Technologies (A) Initiated with "Buy" Rating by HSBC | A Stock News - GuruFocus
GSK makes $2.2B deal for RAPT and its food allergy candidate
Illumina Inc. (ILMN) Shares See Target Boost as Analysts See Potential 2026 Upside - Insider Monkey
The patient retention crisis is happening before enrollment even begins
When every day counts: Building CRO partnerships on a foundation of trust, care and precision
汇丰银行首次覆盖安捷伦股票，给予买入评级，目标价180美元——Investing.com
HSBC initiates coverage on Agilent stock with Buy rating, $180 target - Investing.com
Exciva完成5900万美元B轮融资，用于资助阿尔茨海默病激动药物二期试验。
Exciva raises $59M Series B to fund Phase 2 test of Alzheimer’s agitation drug
Illumina：这条序列的下一步是什么？（纳斯达克股票代码：ILMN）- Seeking Alpha
Illumina: What Is Next In This Sequence? (NASDAQ:ILMN) - Seeking Alpha
Illumina (ILMN) 因十亿细胞图谱制药联盟，看涨前景或将转变 - 雅虎财经新加坡
The Bull Case For Illumina (ILMN) Could Change Following Its Billion Cell Atlas Pharma Alliance - Yahoo Finance Singapore
核苷酸市场即将迎来繁荣 | 安捷伦科技 • 伯乐实验室 • 凯杰公司 - openPR.com
Nucleotide Market Is Going to Boom | Agilent Technologies • Bio-Rad Laboratories • QIAGEN - openPR.com
Is Waters Corporation the Quiet Wall Street Cheat Code Everyone’s Sleeping On? - AD HOC NEWS
沃特世公司是华尔街人人忽视的隐秘制胜法宝吗？——特别报道
Is Waters Corporation the Quiet Wall Street Cheat Code Everyone’s Sleeping On? - AD HOC NEWS
利润回顾：安捷伦科技公司是否显示内部购买 - 季度收益总结与AI驱动股价预测 - baoquankhu1.vn
Profit Recap: Is Agilent Technologies Inc showing insider buying - Quarterly Earnings Summary & AI Driven Stock Price Forecasts - baoquankhu1.vn
赛默飞世尔科技公司（TMO）：看涨理论分析 - 内部人士观察
Thermo Fisher Scientific Inc. (TMO): A Bull Case Theory - Insider Monkey
FDA授予iRegene公司NouvNeu001再生医学先进疗法认定，巩固其作为全球首个同时获得FTD与RMAT认证的iPSC疗法的领先地位。
FDA Grants RMAT Designation to iRegene’s NouvNeu001, Cementing its Lead as the World’s First iPSC Therapy with Both FTD and RMAT Recognitions
阿斯利康签署6.3亿美元协议，获得AbelZeta装甲CAR-T剩余权益。
AstraZeneca pens $630M pact to secure remaining rights to armored CAR-T from AbelZeta